Juniper Biosciences Unveils JBS-002 and JBS-004, Advancing Two Late-Stage Diagnostic Programs to Registration Batch Manufacturing in the Fourth Quarter of 2026

Juniper Biosciences today unveiled two previously undisclosed radiopharmaceutical programs: JBS-002, a Ga-68 based cold kit for prostate cancer imaging, and JBS-004, a fluorine-18 labeled diagnostic ...
Business Insider

Juniper’s JBS-003 (F-MISO) Program Receives FDA Breakthrough Therapy Designation, Advancing a First-in-Class Hypoxia Tracer Enabling Radiation De-escalation in HPV-Positive ...

BEDMINSTER, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Juniper Biosciences today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to JBS-003 ...